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luminal content  [2] , with Bacteroidetes and Firmicutes as 
the most abundant (more than 90%) phyla in humans and 
mammalians  [2–4] . In recent years, the human intestinal 
microbiota has moved increasingly into focus, via re-
search in a variety of medical and biological subdisci-
plines. Its important influence in the development of in-
nate immunity  [5, 6] and the regulation of epithelial de-
velopment or nutrition  [7, 8] is now well established.
 The gut microbiota seems to play an important role in 
the initiation and perpetuation of intestinal inflamma-
tion as seen in animal studies with germ-free maintained 
mouse models, where intestinal inflammation did not 
develop  [9, 10] . Direct evidence for the thesis that intesti-
nal microbes are necessary to initiate and maintain intes-
tinal inflammation in humans was derived from the ob-
servation that, during diversion of the fecal stream, no 
signs of inflammation were apparent in patients with
CD – with prompt recurrence, however, after the restora-
tion of intestinal continuity and the fecal stream  [11] .
 Besides the association of the gut microbiota with
inflammatory bowel disease (IBD) already having been 
known for some time, there is accumulating evidence of 
a role in the pathogenesis of various other disease states, 
such as irritable bowel syndrome  [12, 13] , obesity and the 
metabolic syndrome  [14, 15] . Furthermore, a pathogenic 
role is also suggested in diseases where a link to intestinal 
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recent years. An important prerequisite for the achieved ad-
vances with regard to a better characterization of its com-
plex composition and influencing factors is the increasing 
availability and affordability of culture-independent meth-
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discuss some general aspects of the intestinal microbiota. 
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microbes appears less obvious, such as rheumatoid ar-
thritis  [16] , multiple sclerosis  [17] and even psychiatric or 
behavior disorders including autism  [18] or alcoholism 
 [19] .
 Although our knowledge about alterations in micro-
bial composition in various disease states has increased 
in recent years, achievement of several important re-
search goals in the field of the intestinal microbiota still 
awaits completion:
 What is it exactly, that represents a normal gut micro-
bial composition? What are the main factors influencing 
the composition – predominantly the environment or ge-
netic factors? What is the impact of global variations in 
microbial composition – are the findings and implica-
tions of different studies investigating the gut microbiota 
in health and disease from different countries compara-
ble? Is there a core gut microbiota?
 An essential prerequisite to being able to identify al-
terations in microbial composition in various disease 
states is to characterize a ‘normal’ microbiota as precise-
ly as possible. However, the impressive interindividual 
 [20, 21] (and to a lesser degree intraindividual) differenc-
es with regard to species composition, but also the relative 
abundance of phyla, constitutes a major obstacle. The de-
bate is ongoing as to whether there is a core gut microbi-
ome, i.e. a certain set of universal microbial organismal 
lineages that all human individuals share. For instance, 
although no single bacterial phylotype could be detected 
in abundant frequency in all examined monozygotic and 
dizygotic twin groups, the existence of a core gut micro-
biome at the level of shared genes was postulated  [22] . 
However, as the degree of similarity (revealed to be high-
er in families when compared to unrelated individuals) 
did not differ between monozygotic and dizygotic twins 
in that study, the genetic influence on microbiota compo-
sition appears to be weaker than anticipated. Instead, en-
vironmental factors, such as nutrition, may exert a strong 
influence from early on.
 Based on mathematical models, it can be concluded 
that there is no shared universal species in the gut at the 
1%-level of abundance among all humans. The same 
holds true for the microbiota on human hands at a level 
of 2%  [23] . In this calculation and for several other quan-
titative and qualitative analyses, species was approximat-
ed with a 97% OTU concordance. This means that the 
possibility that we all have bacterial species in common 
in our guts at a high level of abundance can be ruled out. 
And although humans share a group of some ubiquitous 
phyla, the level of abundance is highly variable between 
individuals.
 If there is not a core set of species – what about a core 
set of genes? And what is it that finally counts with re-
gard to intestinal human physiology and immunolo-
gy – the cocktail of various bacterial species or the func-
tion of the multitude of genes provided to the human 
organism?
 Indeed, there is a high level of variability in the abun-
dance of species, but due to a high redundancy the func-
tional state of the whole genome pool may be very similar 
in very different microbial communities  [24] .
 Microbiota and Nutrition/Obesity 
 The intestinal microbiota is not just the umbrella term 
of the sum of microorganisms harbored in the intestine, 
rather, it is a highly complex group of organisms that in-
teract with its host and actively influence its metabolism, 
immunological properties and whole body physiology. 
Well-known examples of these bacterial-derived proper-
ties are the conversion of complex nutrients as well as 
short-chain fatty acids as a nutrient to intestinal epithe-
lial cells, formations of a dense and highly effective de-
fense barrier, the production of essential vitamins e.g. vi-
tamin K, the metabolism of drugs and of bile salt and the 
recirculation or the modification of nutritional com-
pounds that results in transformed products with poten-
tial beneficial (sometimes also hazardous) properties for 
the host, e.g. in nutritional flavonoids.
 Several years ago, an alteration in the relative abun-
dance of the two predominant bacterial phyla – Fir-
micutes and Bacteroidetes – was shown in obese com-
pared to lean mice with a marked increase of the Fir-
micutes to Bacteroidetes ratio of around 50%  [4] . A very 
similar result occurred in human studies  [25, 26] .
 Furthermore, the obese phenotype appeared to be 
transmissible, in that the introduction of an obesity-as-
sociated microbiome into the intestine of germ-free mice 
induced an obese phenotype  [25] .
 A common postulation to explain these findings is an 
increase in the energy extraction in the metabolism of 
enteral food components in a Firmicutes-rich gut micro-
biota. In this respect, a significantly smaller energy con-
tent was found in the feces of obese mice compared to 
their lean counterparts  [25] .
 Interestingly, the opposite procedure, i.e. transplanta-
tion of a ‘lean microbiota’ into germ-free obese mice to 
induce a lean phenotype has not been performed so far.
 However, the question of weight gain in relation to in-
testinal microbial composition is much more complex 
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than just a simple correlation to the ratio of the two most 
abundant phyla. For instance, harvesting of energy could 
not be correlated to the abundance and ratio of the most 
common phyla in a study of adolescents in a structured 
weight-loss program  [27] . Nevertheless, as mentioned be-
low, correlations with successful weight loss were seen go-
ing further down in taxonomy beyond the phylum level. 
Moreover, a study analyzing weight loss after metabolic 
surgery (gastric bypass) found a significant increase in 
the amount of lost kilograms in the group receiving a lac-
tobacillus probiotic for 6 months compared to the place-
bo group  [28] . A direct effect of the lactobacillus strains 
seems rather doubtful, as bacterial overgrowth was si-
multaneously revealed to have decreased in the probiotic 
group, pointing rather towards a contribution of the mi-
crobial composition on the whole.
 So far, it is not possible to relate or even reduce vulner-
ability to obesity to the abundance of a certain phyla or 
set of bacterial species. An interesting approach in in-
creasing our understanding of the key elements that 
make the difference in the microbiota of obese individu-
als would be a comparison of their gut microbial compo-
sition with that of their lean relatives, aiming at the iden-
tification of a core intestinal microbiota for each family 
which harbors the predisposition to obesity  [29] .
 Intriguingly, not only a shift in microbial composition 
was found in a study with obese adolescents on a weight-
loss program (including a low-calorie diet and structured 
physical activity) – the success in losing weight was vari-
able and dependent on the individual’s microbial compo-
sition. Weight loss was substantially higher in individuals 
rich in  Bacteroides fragilis ,  Lactobacillus and  Bifidobac-
terium in relation to  Clostridium coccoides , despite a 
matched dietary intake and an exercise program  [27] .
 What is the nature of this host-microbial interaction 
and what are the mechanisms underlying weight gain in 
altered microbial composition?
 So far, knowledge on these mechanisms is sparse. An 
interesting study, performed more than 10 years ago al-
ready, investigated the intestinal transcription of genes 
with DNA microarrays in germ-free mice that were colo-
nized with  Bacteroides thetaiotaomicron (a Gram-nega-
tive anaerobe) which is a highly abundant member of 
Bacteroidetes in the normal microbiota in both mice and 
humans. Several genes that play an important role in the 
intestinal absorption of lipids were shown to be modu-
lated by the existence of this human commensal archae-
on. Furthermore, the transcription of genes involved in 
other intestinal functions, such as xenobiotic metabo-
lism, maturation of the intestine after birth, angiogenesis 
or even the formation and consolidation of the mucosal 
barrier was also modified  [30] .
 In addition, it has been proposed that there is an inter-
action between the gut microbiota and the host via hor-
monal mechanisms. For instance, short-chain fatty acids, 
that are produced in a higher quantity by an ‘obese mi-
crobiota’ may interact with G-protein receptors  [31] , lead-
ing to an increase in the production of proteins with im-
portant endocrine properties in mediating satiety and the 
regulation of energy metabolism, such as leptins or pep-
tide YY.
 Another potential link between the intestinal micro-
biota and obesity may be a chronic inflammatory state, 
which is known to be an important component of the 
pathophysiology of the metabolic syndrome  [32] . One po-
tential association is via lipopolysaccharide (LPS). LPS 
constitutes an important part of the cell wall in Gram-
negative bacteria and is a well-known very potent stimu-
lator of an inflammatory reaction in the host, e.g. in the 
systemic inflammatory response syndrome and sepsis. It 
has a high affinity to chylomicrons, which are formed in 
the digestive processing of triglycerides, rendering the 
chylomicrons a potential transporter of LPS from the in-
testinal epithelial cells in the systemic circulation  [33] , 
thereby augmenting systemic blood levels.
 The alteration of the intestinal microbiota induced by 
a high-fat diet, specifically the decrease of  Bifidobacteria , 
may modulate the amount of LPS prone to enter the host’s 
blood circulation via a glucaogon-like peptide 2-mediat-
ed increase in the intestinal barrier  [34] .
 Microbiota and IBD 
 The gut microbiota and alterations in its complex 
composition are increasingly considered as a crucial fac-
tor in the pathogenesis of IBD  [9, 35–42] , not just since 
the observations of an improvement in disease activity 
after antibiotic therapy in both CD and UC  [43–45] or the 
absence of spontaneous colitis in germ-free mice  [9, 10] .
 The chicken and egg dilemma evidently applies to the 
interplay of intestinal dysbiosis and IBD and is currently 
still not completely solved. However, an important study, 
investigating microbial composition in washed colonic 
biopsies from patients with IBD and controls, identified 
distinctive microbial abnormalities that correlated with 
disease severity, interestingly in both an inflamed and a 
noninflamed colon specimen  [42] . Further studies fol-
lowed which support a causal role, rather than just effect 
or the role of an innocent bystander.
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 Antigen-presenting cells, such as dendritic cells, are 
essential in microbial recognition as they are capable of 
sensing phylogenetically highly conserved microbial-as-
sociated molecular patterns (MAMPs) via Toll-like re-
ceptors (TLR) or peptidoglycan molecules from the bac-
terial cell walls via nucleotide-binding oligomerisation 
domain (NOD)-like receptors (NLR).
 It appears that at least some of the intestinal bacteria 
influence the establishment of an immune tolerogenic re-
sponse through an induction of regulatory T cells and 
IgA secretion via dendritic cells.
 Furthermore, it was shown, that not only bacteria but 
also their metabolic products may modulate the host’s 
immune response. For instance, polysaccharide A, pro-
duced by  Bacteroides fragilis , a human symbiontic bacte-
ria, was shown to induce an immune-modulating immu-
nological response, providing protection from exhaustive 
inflammatory response induced by  Helicobacter hepati-
cus , in that the immune response was attenuated includ-
ing the production of IL-10 and suppression of proin-
flammatory cytokines  [46] .
 Moreover, a chronic stimulation of NOD-2 in human 
macrophages led to a decreased proinflammatory re-
sponse, evident in a decrease of TNF-  , IL-8 and IL-1  , 
when these cells were restimulated after pretreatment 
 [47] .
 Accordingly, the gut microbiota and the induced tol-
erance of the host seem to simultaneously assure protec-
tion from invasive pathogens and also from an overre-
acting inflammatory response. The disruption of this 
homeostatic coexistence between gut microbiota and the 
host, including the latter’s physiologic immune toler-
ance, is assumed to have a central role in IBD pathogen-
esis  [40, 48] .
 In recent years, a magnitude of studies looked at the 
composition of the commensal microbiota in IBD pa-
tients compared to healthy controls or to patients with 
other diseases. One characteristic finding is a reduced 
microbial diversity in patients with IBD  [39, 49–51] . Fur-
ther distinctive characteristics of microbial composition 
in patients with IBD compared to healthy controls have 
been described, sometimes with conflicting results, in-
cluding alterations on the phylum level like a reduction 
of Firmicutes and Bacteroidetes and concomitant in-
crease in the fraction of Proteobacteria and Actinobacte-
ria  [36, 52, 53] .
 Other studies identified characteristic shifts on the 
species level  [54] , such as a combination of  Dialister invi-
sus , a hitherto uncharacterized member of the Clostri-
diacae family,  Faecalibacterium prausnitzii ,  Bifidobacte-
rium adolescentis and  Ruminococcus gnavus as being in-
dicative of dysbiosis associated with CD  [55] .
 Even within a specific form of IBD, differences of mi-
crobiota composition were shown according to the phe-
notype. For instance, in CD patients with ileal disease, 
the disappearance of well-known commensals  (Faecali-
bacterium and Roseburia) and an increase in Enterobac-
teriaceae and  Ruminococcus gnavus were found  [56] .
 However, some intestinal microbes seem to have pro-
tective effects and are therefore used as therapeutic agents 
in IBD, especially UC  [57, 58] . Potential mechanisms un-
derlying this clinical benefit might be an attenuation of 
adherence and consecutive invasion of pathogenic intes-
tinal  Escherichia coli strains  [59] as well as the positive 
effects of probiotic bacteria on mucosal integrity, the se-
cretion of proinflammatory cytokines and the induction 
of   -defensins  [60–63] .
 Finally, the assumption that IBD may be related to a 
single microbial cause – hence being an infectious disease 
with a hitherto unidentified agent – is not a new one, but 
was most likely postulated as soon as research on IBD 
pathogenesis began. Since then, a variety of candidate 
agents have been proposed, including mycobacteria (pre-
dominantly  Mycobacterium avium paratuberculosis ), En-
terobacteriaceae, such as  E. coli strains,  Listeria monocy-
togenes and also viral agents, such as paramyxovirus or 
reroviridae. However, so far, no single agent has been iso-
lated in all – or at least the vast majority of – affected pa-
tients with high consistency and the results of therapeutic 
trials of antimicrobial agents directed at candidate patho-
gens have been at best inconclusive, arguing against a sin-
gle microbial organism harboring a key role in the patho-
genesis of IBD.
 Microbiota and Graft versus Host Disease 
 Another intestinal disease, where a pathogenic role of 
the gut microbiota is assumed is graft versus host disease 
(GVHD). Bearing in mind the common occurrence of 
infectious complications in GVHD, including severe life-
threatening septicemia often due to Gram-negative rods, 
a link between the gut microbiota and GVHD suscepti-
bility was already suggested in the 60s and 70s of the last 
century  [64, 65] .
 In an animal model of GVHD – syngenic GVHD 
(SGVHD), where lethally irradiated rodents receive an 
autologous bone marrow transplantation followed by cy-
closporine A – a form of colitis develops that is not dis-
tinguishable from other murine colitis models for IBD, 
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revealing similar microscopic findings, activation of a 
similar phenotype of CD4+ effector T cells and also a cy-
tokine profile  [66] . Interestingly, the in vitro responsive-
ness of these CD4+ T cells from these animals suffering 
from GVHD-related colitis showed an increase activity 
against bacterial antigens, which were isolated from the 
fecal supernatant of normal animals  [67] .
 In a recent study, an increased responsiveness of CD4+ 
T cells against microbial antigens from the cecal content 
of normal animals was shown in a murine model. If ani-
mals were treated with a broad-spectrum antibiotic com-
bination of metronidazole and ciprofloxacin after trans-
plantation, no clinical symptoms or characteristic patho-
logical lesions in the intestine of cyclosporine-A-treated 
animals were observed. On an immunological level, the 
previously mentioned enhanced responsiveness of CD4+ 
T cells was likewise significantly decreasing, including 
decreased levels of various proinflammatory cytokines, 
such as IFN-  , IL-17 and TNF-  . These findings led the 
authors to suggest an important pathogenic role of the 
intestinal microbiota in SGVHD  [68] .
 Another study in mice identified the Paneth cells as a 
potential target in GVHD, hereby inducing a decrease in 
the expression and secretion of   -defensins, which have 
been shown to be an important defense strategy against 
pathogenic bacteria. The subsequent decrease of secre-
tion of this antimicrobial peptide induced a loss of micro-
bial diversity, predominantly with regard to commensals, 
hence increasing the abundance of Gram-negative bacte-
ria, which are a well-established origin of systemic blood-
stream infection.
 Interestingly, the degree of GVHD correlated with the 
degree of microbial alterations. Moreover, the use of poly-
myxin B, which has the potential to limit the often ob-
served overgrowth of  E. coli in GVHD, attenuated or even 
improved the severity of the inflammatory affection of 
the gut  [69] . Likewise, the induced shifts towards a pro-
inflammatory gut microbiota in another murine study of 
GVHD was shown to be depending on TLR sensing 
(MyD88/TLR9), with a decreasing extent of intestinal pa-
thology in TLR9-deficient mice or antagonizing therapy 
with a synthetic oligonucleotide inhibiting TLR9  [70] . In 
conclusion, these findings suggest that – very similar to 
the proposed role in the pathogenesis of IBD – an induced 
dysbiosis represents both a key element in the develop-
ment of GVHD but also a potential target of therapeutic 
strategies aiming at manipulating microbial composi-
tion.
 Investigating Microbial Composition in Humans 
Undergoing Smoking Cessation 
 Smoking has emerged as an important environmental 
factor influencing the course of IBD, with differing ef-
fects in UC and CD. Tobacco smoking has a protective 
effect in UC. The opposite is true for CD, where smoking 
has a detrimental influence on the future disease course. 
In addition, the risk of developing UC in former smokers 
is substantially elevated compared to never-smokers  [71–
76] , and the course of the disease is milder in former 
smokers who resume smoking  [77, 78] .
 Moreover, it is well known that smokers who success-
fully quit smoking gain weight – on average about 7–8 kg 
in around 80% of individuals  [79] . Although one would 
intuitively assume that this weight gain is related to an 
increase in food intake, data addressing this issue are 
equivocal. For instance, a small study conducted around 
25 years ago did not detect an increase in total calorie in-
take in the people who quit smoking and gained weight, 
although an increase in carbohydrate calories compared 
to protein calories was observed  [80] . A very large (361,662 
men screened and 12,866 randomized) population-based 
primary prevention trial, the Multiple Risk Factor Inter-
vention Trial (MRFIT), conducted in North America, 
which investigated the clinical effect on multiple cardio-
vascular risk factors, found the following interesting re-
sults with regard to smoking cessation and weight gain: 
intriguingly, successful quitters showed a reduced calorie 
intake compared to those who continued or resumed 
smoking, and also a generally healthier diet composition. 
Nevertheless, a weight gain was exclusively observed in 
men who ceased smoking, while men who continued or 
resumed smoking lost body weight  [81] .
 We aimed to investigate whether smoking cessation in 
healthy individuals leads to a change of the composition 
of the gut microbial composition. We therefore followed 
up a group of 10 smokers during smoking cessation (in-
tervention group) over a period of 9 weeks with a pre-
specified complete cessation of smoking after the first 
week, and compared these results to 10 control subjects, 
5 nonsmokers and 5 continuing smokers. Stool samples 
were obtained 1 week before as well as 4 and 8 weeks after 
smoking cessation. The hitherto unpublished results re-
vealed firstly an overall change in the microbial composi-
tion in the intervention group as indicated by analyses of 
terminal restriction fragment length polymorphisms 
with doubly-centered principal component analyses.
 Secondly, the sequences obtained by pyrosequencing 
showed statistically significant changes in the interven-
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tion group but not in the 2 control groups. Significant 
differences were observed on the phylum level with an 
increase in relative abundance of Firmicutes and Actino-
bacteria and a decrease of Proteobacteria. In addition, 
significant changes on the genus level were found, again 
exclusively in the intervention group. Phylogenetic diver-
sity showed an increase in the intervention group after 
smoking cessation.
 Our investigations show that smoking status influenc-
es the composition of the gut microbiota and that smok-
ing cessation leads to significant changes in intestinal mi-
crobial composition. These results point to a potential 
pathophysiological link between smoking status and 
IBD, and furthermore, imply that an alteration in micro-
bial composition and consecutive extraction of energy by 
the host may play a role in weight gain after smoking ces-
sation.
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